Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Choreo LLC

Choreo LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 249.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,785 shares of the biopharmaceutical company’s stock after acquiring an additional 2,702 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals were worth $4,000,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the last quarter. Capital World Investors raised its holdings in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after buying an additional 23,146 shares during the period. Capital International Investors lifted its stake in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares in the last quarter. Putnam Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after buying an additional 24,329 shares during the period. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $932,571,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,561 shares of company stock valued at $13,095,105. Insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on REGN. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. TD Cowen upped their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Truist Financial restated a “buy” rating and set a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,109.70.

Regeneron Pharmaceuticals Stock Up 1.2 %

Regeneron Pharmaceuticals stock opened at $1,144.77 on Tuesday. The firm has a market cap of $126.20 billion, a price-to-earnings ratio of 33.82, a P/E/G ratio of 3.86 and a beta of 0.12. The firm has a fifty day moving average price of $1,114.85 and a two-hundred day moving average price of $1,021.92. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.79 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.